Understanding regenerative medicine: a commissioner's viewpoint.

Area of Science:

• Regenerative Medicine
• Healthcare Policy
• Health Economics

Background:

• Regenerative medicines (RMs) are an emerging class of therapeutics.
• Healthcare commissioners require methods to assess RM safety and efficacy.
• Evaluating RMs is crucial for patient outcomes and resource allocation.

Purpose of the Study:

• To provide a pragmatic framework for evaluating regenerative medicines.
• To differentiate between currently useful and future RMs.
• To inform healthcare commissioners and RM developers on essential data for adoption.

Main Methods:

• The study reflects on practical issues encountered in funding RMs.
• It proposes criteria for assessing the current utility of RMs.
• The approach considers the integration of RMs into existing care pathways.

Main Results:

• A method is presented to distinguish between RMs with current clinical utility and those with future potential.
• Key information requirements for RM adoption are identified.
• The framework aims to support informed decision-making in RM commissioning.

Conclusions:

• A structured approach is necessary for evaluating and funding regenerative medicines.
• Distinguishing current from future utility is vital for effective healthcare resource allocation.
• This framework supports evidence-based adoption of regenerative medicine products.